Aerie Launches Rhopressa in US as Treatment for Lowering IOP

May 4, 2018: By Jon Swedien

Aerie Pharmaceuticals has launched Rhopressa in the US, the Durham, North Carolina, company announced April 30.

Aerie forecasts the open-angle glaucoma and ocular hypertension treatment will net $20 million to $30 million in 2018, the company said in March.

Rhopressa (netarsudil ophthalmic solution) 0.02% gained US FDA approval in December 2017. It is a rho-associated protein kinase (rho kinase, or ROCK) inhibitor, a new class of medications proposed to lower intraocular pressure (IOP) by directly increasing trabecular outflow. The eye drop is administered once daily.

The company’s national sales force is now providing product information and samples to physicians, said Aerie Chairman and CEO Vicente Anido Jr., PhD.

The company said it expects to gain preferred formulary coverage for the majority of commercial payers for Rhopressa by late 2018, with most of the Medicare Part D coverage expected to start in 2019.

Aerie is also developing a second IOP-lowering product candidate—Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%. It is also a once-daily eye drop.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US Health Secretary Alex Azar Takes Aim at Rebates in US Senate Hearing

Beyeonics Surgical Raises $11.5 Million in Initial Funding Round

MeiraGTx Raises $75 Million in Initial Public Offering

GenSight to Pursue Approval for LHON Gene Therapy Candidate, Despite Phase III Setback

Optovue Receives FDA Clearance for AngioAnalytics, First OCT Angiography Metrics

Nexy Robotic Retinal Imaging System Receives FDA Clearance

Ocutrx Receives US Patent for Oculenz AR Glasses for Macular Degeneration

Allergan’s Bimatoprost SR Demonstrates Noninferiority to Timolol in Phase III Glaucoma Study

KKR to acquire Envision Healthcare, Including Amsurg ASC Business

Ophthalmologist Carmen Puliafito, MD, Seeks to Regain Medical License

Avedro Gains J Code for Photrexa Formulations in Preliminary CMS Decision

EyeGate Seeks to Study Ocular Bandage Gel in Punctate Epitheliopathy

Nicox, Ironwood to Collaborate on Novel Ophthalmic Treatments

US FDA Approves MDGH’s Moxidectin for Treatment of River Blindness

Bausch + Lomb Enrolls First Patient in Trial for enVista MX60EF Trifocal IOL

Cincinnati Eye Institute Partners with Private Equity Firm to Pursue National Expansion

Ophthotech Enters Gene Therapy Deals with University of Florida, University of Pennsylvania

Teva’s Launches Generic Version of Restasis in Canada

Clearside’s Phase II Trial for DME Candidate Meets Primary Endpoint

Orasis Raises $13 Million in Series B Financing

Coming soon

2018 Glaucoma Device Report: A Global Market Analysis for 2017 to 2023